Biorce closes a $52.5 million funding round to accelerate the development of its artificial intelligence software for clinical trials

Biorce has closed a $52.5 million investment round (approximately €44.3 million) with the aim of accelerating the development of its artificial intelligence software for clinical trials and strengthening its international expansion, particularly in the United States. Founded in Barcelona two years ago, the company will use the funds to expand the capabilities of Aika, its AI platform, and to scale its team.

The round was led by DST Global, one of the world’s leading venture capital firms, with historic investments in companies such as Facebook, Alibaba and Spotify. Existing shareholders Norrsken VC, YZR Capital and Mustard Seed Maze also participated in the round, alongside Endeavor Catalyst and a group of prominent individual investors, including Nik Storonsky, CEO of Revolut; Arthur Mensch, co-founder and CEO of Mistral AI; Paulo Rosado, founder of OutSystems; Albert Nieto, founder of Seedtag; Stef Van Grieken, co-founder of Cradle; and Alex Berriche, founder of Fleet.

“This round reflects both the scale of the problem we are addressing and the market’s confidence in our vision,” said Pedro Coelho, co-founder and CEO of Biorce, who believes the capital raised represents a “validation” of the company’s technology, team and potential. With this transaction, Biorce has now raised more than €50 million since its inception.

The company is developing an artificial intelligence platform that simplifies the design and execution of clinical trials, from patient selection to the choice of hospitals, with the aim of reducing inefficiencies in a sector characterized by high costs and lengthy validation timelines. “We cut by 50% the time spent preparing and processing the paperwork involved in these highly complex processes,” Coelho said. The company’s mission is for “trials to be faster, more reliable and more accessible, so that patients can benefit sooner from new treatments.”

Biorce was founded in 2024 in Barcelona by Pedro Coelho together with Clara Bernardes, José Faria and Diogo Pisoeiro, all of them Portuguese. “We chose Barcelona for its international appeal and the availability of technological talent,” the entrepreneur explained. “I had a new idea and decided to test it in the United States. It worked, and when returning to Europe we opted for Barcelona, as things became more complicated with Brexit,” he recalled.

Since its launch, the startup has secured close to 50 clients in the pharmaceutical sector, mainly in the United States, as well as in Europe and Asia. “Last year, we generated more than €10 million in revenue and employed 60 people. We have offices in Barcelona, New York, London and Lisbon,” the CEO said. For 2025, the company expects revenues of approximately €12 million and to reach net profitability.

Following this Series A round, Biorce plans to accelerate its growth with the opening of an R&D center in Austin, Texas, in order to be closer to the U.S. pharmaceutical and biotech ecosystem, as well as the expansion of its headquarters in Barcelona. The company expects to end the year with a workforce of 250 employees, with new hires split evenly between Barcelona and Austin